Results from recent clinical trials of antibodies that target amyloid-β (Aβ) for Alzheimer's
disease have created excitement and have been heralded as corroboration of the amyloid …

Since the advent of induced pluripotent stem cell (iPSC) technology a decade ago,
enormous progress has been made in stem cell biology and regenerative medicine. Human …

Animal models of human diseases that accurately recapitulate clinical pathology are
indispensable for understanding molecular mechanisms and advancing preclinical studies …

Experimental models of Alzheimer's disease (AD) are critical to gaining a better
understanding of pathogenesis and to assess the potential of novel therapeutic approaches …

Alzheimer's disease (AD) is characterized by the accumulation of amyloid-β and tau. We
previously reported that administration of bone marrow mesenchymal stem cells (BM-MSCs) …

Accumulation of amyloid‐β (Aβ) and fibrillary tangles, as well as neuroinflammation and
memory loss, are hallmarks of Alzheimer's disease (AD). After almost 15 years from their …

Age-associated neurological diseases represent a profound challenge in biomedical
research as we are still struggling to understand the interface between the aging process …

Alzheimer's disease is a neurodegenerative disorder mainly characterized by β-amyloid
deposit and tau hyperphosphorylation with no curative treatments. Curcumin (Cur) has been …

Abstract The Alzheimer's Association's Research roundtable met in April 2015 to explore the
role of neuroinflammatory mechanisms in the progression of Alzheimer's disease (AD). The …

Alzheimer's disease (AD) has no currently approved disease-modifying therapies (DMTs),
and treatments to prevent, delay the onset, or slow the progression are urgently needed. A …